Search results for "interactions"

showing 10 items of 1963 documents

Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry.

2021

PURPOSE The aim of this study was to analyze the epidemiology of polypharmacy in hospital psychiatry. Another aim was to investigate predictors of the number of drugs taken and the associated risks of drug-drug interactions and potentially inappropriate medications in the elderly. METHODS Daily prescription data were obtained from a pharmacovigilance project sponsored by the Innovations Funds of the German Federal Joint Committee. RESULTS The study included 47 071 inpatient hospital cases from eight different study centers. The mean number of different drugs during the entire stay was 6.1 (psychotropic drugs = 2.7; others = 3.4). The mean number of drugs per day was 3.8 (psychotropic drugs …

DrugMalemedicine.medical_specialtyEpidemiologymedia_common.quotation_subjectInappropriate Prescribing030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsPharmacovigilanceEpidemiologyMedicineHumansPharmacology (medical)Drug Interactions030212 general & internal medicineRisk factorPsychiatryPotentially Inappropriate Medication Listmedia_commonAgedPolypharmacyPsychiatrybusiness.industryPharmacoepidemiologyHospitalsPsychotropic drugPharmaceutical PreparationsPolypharmacyFemalebusinessPharmacoepidemiology and drug safetyREFERENCES
researchProduct

Influence of drug polarity upon the solid-state structure and release properties of self-emulsifying drug delivery systems in relation with water aff…

2009

To overcome low oral bioavailability of poorly water-soluble drugs, self-emulsifying drug delivery systems (SEDDS) have been noted as a promising strategy. However, incorporation of drugs into SEDDS composed of Gelucire44/14 could induce interactions not yet well understood. The aim of this study was to investigate the influence of drug polarity upon the solid-state structure of SEDDS formulation, particularly in terms of wettability, thermal behaviour and microscopic aspects and their effect upon the release properties of the SEDDS. Model drugs were naproxen and sodium naproxen (10% w/w), two drugs with similar chemical structure but different water solubilities. Both drugs had an effect o…

DrugNaproxenmedia_common.quotation_subjectChemical structureNaproxen SodiumSolid state structurePolyethylene GlycolsColloid and Surface ChemistryDrug Delivery SystemsmedicinePhysical and Theoretical ChemistrySolubilitymedia_commonChromatographyCalorimetry Differential ScanningChemistryWaterSurfaces and InterfacesGeneral MedicineBioavailabilityKineticsChemical engineeringEmulsifying AgentsDrug deliveryMicroscopy Electron ScanningHydrophobic and Hydrophilic InteractionsBiotechnologymedicine.drugColloids and surfaces. B, Biointerfaces
researchProduct

Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine

2015

Literature data relevant to the biopharmaceutical properties of the active pharmaceutical ingredient (API) nifedipine are reviewed to evaluate whether a waiver of in vivo bioequivalence (BE) testing of immediate-release (IR) dosage forms formulated as tablets and soft gelatin capsules is warranted. Nifedipine's solubility and permeability, its therapeutic use and index, pharmacokinetics, food drug interactions, and any reported BE/bioavailability problems were all taken into consideration. Solubility and BA data indicate conclusively that nifedipine is a class II substance of biopharmaceutics classification system (BCS) and that the formulation of drug product plays a key role on the dissol…

DrugNifedipineChemistry Pharmaceuticalmedia_common.quotation_subjectPharmaceutical ScienceCapsulesBioequivalencePharmacologyDosage formExcipientsFood-Drug InteractionsNifedipinePharmacokineticsmedicineAnimalsHumansmedia_commonActive ingredientChemistryCalcium Channel BlockersBiopharmaceutics Classification SystemBioavailabilityIntestinal AbsorptionSolubilityTabletsmedicine.drugJournal of Pharmaceutical Sciences
researchProduct

Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor

2001

Awareness of important differences in the pharmacological profile of individual optical isomers of chiral drugs led to the development of esomeprazole, the S-isomer of omeprazole, a new pharmacological entity designed to improve the clinical outcome of available proton pump inhibitors in the management of acid-related disorders. The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump.

DrugPeptic Ulcermedicine.drug_classmedia_common.quotation_subjectProton-pump inhibitorPharmacologyEsomeprazolelaw.inventionZollinger-Ellison SyndromelawmedicineHumansDrug InteractionsOmeprazoleRandomized Controlled Trials as Topicmedia_commonClinical pharmacologyHepatologybusiness.industryGastroenterologyEsomeprazoleProton Pump InhibitorsAnti-Ulcer AgentsBioavailabilityProton pumpSafety profilebusinessOmeprazolemedicine.drugDigestive and Liver Disease
researchProduct

Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection

2021

The identification of chemical compounds able to bind specific sites of the human/viral proteins involved in the SARS-CoV-2 infection cycle is a prerequisite to design effective antiviral drugs. Here we conduct a molecular dynamics study with the aim to assess the interactions of ivermectin, an antiparasitic drug with broad-spectrum antiviral activity, with the human Angiotensin-Converting Enzyme 2 (ACE2), the viral 3CLpro and PLpro proteases, and the viral SARS Unique Domain (SUD). The drug/target interactions have been characterized in silico by describing the nature of the non-covalent interactions found and by measuring the extent of their time duration along the MD simulation. Results …

DrugProteasesIn silicomedia_common.quotation_subjectProtein domainCoronavirus Papain-Like ProteasesGeneral Physics and AstronomyPlasma protein bindingBiologyAntiviral AgentsivermectinProtein DomainsMolecular dynamics simulationHumansPhysical and Theoretical ChemistryBinding siteCoronavirus 3C Proteasesmedia_commonchemistry.chemical_classificationSARS Unique DomainBinding SitesSARS-CoV-2SARS-CoV-2 infectionRNAHydrogen BondingVirologyG-QuadruplexesMolecular Docking SimulationEnzymechemistrySettore CHIM/03 - Chimica Generale E InorganicaRNAAngiotensin-Converting Enzyme 2Hydrophobic and Hydrophilic InteractionsProtein BindingPhysical Chemistry Chemical Physics
researchProduct

An overview of statin-induced myopathy and perspectives for the future

2020

Introduction: Statins remain the most commonly prescribed lipid-lowering drug class for the treatment of atherosclerotic cardiovascular disease. Their well-recognized side effects are known as statin-associated muscle symptom (SAMS). Some advances in this field have been made in recent years, but the understanding of the mechanisms has lagged. Investigating the specific role of the anti-HMGCR autoantibody, pharmacokinetic genetic variants, characterization of the known phenotypes of statin toxicity, in relation to clinical markers of disease, is of high importance. Areas covered: We summarized currently available findings (on PubMed) related to SAMS and discussed the therapeutic approaches,…

DrugStatinUbiquinonemedicine.drug_classmedia_common.quotation_subjectHyperlipidemiasDiseasetherapeutic approaches030204 cardiovascular system & hematologyBioinformaticsPharmacogenomic Variants03 medical and health sciences0302 clinical medicineMuscular DiseasesRisk FactorsmedicineAnimalsHumansDrug InteractionsPharmacology (medical)Adverse effectHypolipidemic Agentsmedia_commondrug interactionbusiness.industryGeneral MedicineAtherosclerosisStatin induced myopathystatin-induced myopathyunderlying mechanismDrug classrisk factor030220 oncology & carcinogenesisCoenzyme Q10Hydroxymethylglutaryl-CoA Reductase Inhibitorsmyositis autoantibodieRisk assessmentbusinessstatin-associated muscle symptom
researchProduct

Differential interactions of the broad spectrum drugs artemisinin, dihydroartemisinin and artesunate with serum albumin

2013

Artemisinin is a drug, widely used in malaria treatment. As the binding affinity of artemisinin and its derivatives dihydroartemisinin and artesunate to blood serum proteins might influence the effectiveness of the drug, binding of artemisinin and derivatives to serum albumin was studied under near physiological conditions. Binding kinetics indicate a simple, single-step association process for all artemisinin derivatives. The determined changes in enthalpy and entropy upon drug binding clearly indicate that hydrophobic forces are most important for artemisinin and dihydroartemisinin binding, whereas binding of artesunate is governed by both hydrophilic and hydrophobic forces. Key residues,…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentSerum albuminArtesunatePharmaceutical ScienceDihydroartemisininPharmacologyHydrophobic effectchemistry.chemical_compoundBlood serumparasitic diseasesDrug DiscoverymedicineAnimalsArtemisininSerum Albuminmedia_commonPharmacologybiologyChemistryArtemisininsReceptor–ligand kineticsMalariaComplementary and alternative medicineBiochemistryArtesunatebiology.proteinMolecular MedicineCattleDrug Therapy CombinationHydrophobic and Hydrophilic InteractionsProtein Bindingmedicine.drugPhytomedicine
researchProduct

Recent progress in the pharmacotherapy of cancer pain.

2001

Cancer pain can be relatively well managed with primary therapies, according to the WHO ladder. However, different conditions may limit the response to the analgesic drug used, which are mainly oploids. Specifically, adverse effects may prevail against the analgesic activity in the clinical setting. New pharmacological strategies may enable a more satisfactory response to be obtained, in terms of balance between analgesia and adverse effects. The change of route of administration or the use of alternative opioids is a first-line option. The use of adjuvant drugs may also improve analgesia with different mechanisms. Recent studies have demonstrated the value of these alternative approaches. …

Drugmedicine.medical_specialtyAnalgesicsbusiness.industrymedicine.medical_treatmentmedia_common.quotation_subjectAnalgesicPainPain ladderRoute of administrationPharmacotherapyOncologyAnesthesiaNeoplasmsmedicineHumansPharmacology (medical)Drug InteractionsIntensive care medicineCancer painAdverse effectbusinessAdjuvantmedia_commonExpert review of anticancer therapy
researchProduct

Herbal hepatotoxicity: a hidden epidemic

2011

Complementary and alternative therapies, including herbal products, have become increasingly popular in the general population and among patients and physicians. Regulations and pharmacovigilance regarding herbal drugs are still incomplete and need to be improved. In fact, herbals are commonly marketed on the Internet, and in many countries they are sold as food supplements, which are beyond the control of drug regulatory agencies. In Europe and the U.S., reports of hepatotoxicity from these products, including those advertised for liver diseases, are accumulating. Many herbal drugs are also commonly used in children, and in women during pregnancy and lactation, because they are believed to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectPopulationHerb-Drug InteractionsMEDLINEAlternative medicinecomplex mixtureslaw.inventionRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawPharmacovigilanceInternal MedicineHumansMedicineMedical prescriptioneducationIntensive care medicineHerbal remedies Dietary supplement Slimming aids Hepatotoxicity Preventionmedia_commoneducation.field_of_studyTraditional medicinebusiness.industrymedicine.diseaseDietary SupplementsEmergency MedicineChemical and Drug Induced Liver InjurybusinessPhytotherapyInternal and Emergency Medicine
researchProduct

Fast Regulation of Cytochrome P450 Activities by Phosphorylation and Consequences for Drug Metabolism and Toxicity

2002

In contrast to the well-known regulation of cytochrome P450 (CYP) activity by enzyme induction, which represents a process with slow onset and slow offset, more recent studies revealed phosphorylation as a fast (within observation instantaneous) and isoenzyme-selective regulation. The phosphorylated enzyme (investigated isozyme: CYP2B1) was fully inactive. The phosphorylation is mediated by PKA and hence under control of hormones and drugs that alter cellular cAMP levels. The consequences for the metabolic control of toxic species derived from drugs and environmental carcinogens are discussed. This information will help to improve therapy with drugs metabolized by CYPs which are phosphoryla…

Drug-Related Side Effects and Adverse ReactionsClinical BiochemistryPharmacologyBiochemistryIsozymeCytochrome P-450 Enzyme SystemCyclic AMPAnimalsHumansDrug InteractionsPhosphorylationEnzyme inducerMolecular BiologyCarcinogenchemistry.chemical_classificationbiologyCytochrome P450Cyclic AMP-Dependent Protein KinasesHormonesIsoenzymesenzymes and coenzymes (carbohydrates)EnzymePharmaceutical PreparationsBiochemistrychemistryCytochrome P-450 CYP2B1ToxicityCarcinogensbiology.proteinPhosphorylationDrug metabolismBiological Chemistry
researchProduct